Abiodun Jimoh
CHI Pharmaceuticals, a member of the Tropical General Investment (TGI) Group, and EVA Pharma, a leading global healthcare solutions provider, have announced a strategic partnership to expand access to essential medicines for patients in Nigeria. The partnership will leverage CHI Pharmaceuticals’ local expertise and EVA Pharma’s extensive portfolio to address pressing patients’ needs in metabolic health, diabetes, virology, and hepatitis B.
The collaboration was unveiled at an event in Lagos, Nigeria, attended by EVA Pharma’s Nigeria Country Manager, David Otokpa, and Marketing Lead of West Africa, Bishoy Faltas. The partnership aims to improve healthcare outcomes in Nigeria by providing high-quality and affordable healthcare products.
Shriram Iyer, COO of CHI Pharmaceuticals, highlighted the strategic alignment between the companies, stating, “We are excited to collaborate with EVA Pharma, a company renowned for its innovative approach and patient-centric solutions. This partnership demonstrates our ongoing commitment to providing Nigerians with high-quality and affordable healthcare products.”
Bishoy Faltas, Marketing Lead for West Africa at EVA Pharma, described the collaboration as a significant milestone in their mission to support communities across Africa by providing innovative and accessible healthcare solutions.
Dr. Sylvia Vito, Sub-Sahara Africa Head at EVA Pharma, emphasized the importance of the collaboration, stating, “We are deeply committed to improving access to essential healthcare across the Sub-Sahara region through partnerships and collaborations with local and regional companies and entities to ensure that life-saving treatments reach patients.”
The partnership is expected to significantly enhance sustainable access to essential medicines in Nigeria, ultimately improving citizens’ health and well-being.
